Anthony Faugno, MD
Pulmonary Disease · Boston, MANPI 1992067698
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $131,750 of the $131,900 with a category attached, or 99.9%. Modernatx, Inc. accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $131,769 and has fallen 100.0% since, to $36 in 2025. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 9 payments — averaging $14,656 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$132K
- Alnylam Pharmaceuticals Inc.$114
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$36
Across 11 payments — averaging $63,909 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$703K
What the payments were for
- Consulting fees$131,750100%
- Travel & lodging$950%
- Food & beverage$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 6 | $131,750 |
| Alnylam Pharmaceuticals Inc. | 2 | $114 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Moderna Covid-19 Vaccine$131,750
How this compares
$131,900 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
- Kelsey SackBoston$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.